Led · Equity · Oct 2025

Mission Therapeutics is a clinical-stage biotechnology company headquartered in Cambridge, UK, focused on promoting the removal of dysfunctional mitochondria to restore cellular health. Its lead candidate, MTX325, inhibits the mitochondrial DUB enzyme USP30 and is being advanced for central-nervous-system disorders, with an upcoming Phase Ib proof-of-mechanism study in Parkinson’s disease patients. A second program, MTX652, targets peripheral indications using the same mitophagy-enhancing approach. Recent Phase Ia studies, including PET imaging, confirmed that MTX325 penetrates functional brain tissue in healthy volunteers, de-risking further clinical work. The company’s development efforts are additionally supported by a $5.2 million grant from the Michael J. Fox Foundation and Parkinson’s UK. Mission Therapeutics is led by Executive Director Dr. Anker Lundemose, Chief Development Officer Dr. Sarah J. Fritchley, and Chairman Dr. James B. Summers.

Participated · Series C · Dec 2022

Carrick Therapeutics is developing a portfolio of differentiated oncology therapies, including samuraciclib and a novel CDK12/13 inhibitor/Cyclin-K glue-degrader. The company plans to use recent financing to fund ongoing and planned samuraciclib clinical trials and advance IND-enabling toxicology studies for the CDK12/13 program. Management has highlighted CDK7 and CDK12/13 inhibitors as priority assets and intends to accelerate their development across multiple indications. Carrick announced a collaboration and a $35 million investment from Pfizer while retaining full economic ownership and control of samuraciclib and the rest of its pipeline. The company stated proceeds will also be used for working capital and general corporate purposes. The press release lists Dublin, Ireland and Boston as locations for the company. Carrick is building a portfolio of first-in-class cancer treatments that target driver mechanisms of the most aggressive and resistant forms of cancer and aims to tailor therapies to individual patients' tumours. The company plans to progress multiple programmes through hit-to-lead and lead optimisation with the goal of delivering multiple development candidates. To support this work, Evotec will provide its full range of discovery and oncology services via its discovery and pre-clinical platform. Carrick is headquartered in Dublin with R&D located in Oxford and Dublin. The company recently completed a $95M funding round led by ARCH Venture Partners and Woodford Investment Management with participation from Cambridge Enterprise Seed Funds, Cambridge Innovation Capital, Google Ventures (GV), Lightstone Ventures and Evotec AG. Evotec will invest up to $6M towards the round and said the partnership will allow Carrick to rapidly progress its pipeline. No further financial details were disclosed, and Evotec stated its financial guidance for 2016 remains unchanged despite the investment.

Participated · Equity · Feb 2017

Modus Therapeutics is focused on advancing its lead drug candidate, sevuparin, for the treatment of chronic kidney disease. The company’s recent financing underscores strong market confidence in its clinical program, with the unit issue being oversubscribed at a 189 percent subscription rate. Proceeds from the raise will fund continued development of sevuparin and support the company’s operations through the end of 2026. As part of Karolinska Development AB’s portfolio, Modus Therapeutics benefits from access to a strong Nordic life-sciences network and expertise in bringing medical innovations to market. The company positions sevuparin as a potential new therapeutic option for a serious unmet medical need. Current financial planning suggests sufficient runway for at least the next two and a half years. No additional operating metrics such as revenue or patient enrollment figures were disclosed in the article.

Led · Series B · Feb 2014

Novimmune is a privately held Swiss biopharmaceutical company headquartered in Geneva that discovers and develops antibody-based drugs. Its pipeline targets inflammatory and rare diseases, immune-related disorders, and cancer, including therapies aimed at conditions such as Hemophagocytic Lymphohistiocytosis (HLH). The company focuses on targeted antibody-based therapies as its core product approach. Novimmune said it plans to further develop novel medicines to provide improved treatment options for patients with rare and devastating diseases, autoimmune and inflammatory diseases, and cancer. Financially, the company completed a CHF30 million (US$29.8 million) funding round driven by major commitments from lead investors and broad participation from existing shareholders. Eduard Holdener is Chairman and CEO. Novimmune is focused on creating medicines for patients in need, emphasizing next-generation antibody therapeutics and orphan-disease applications. The company advances clinical-stage candidates including NI-0501 (for a life‑threatening orphan disease) and NI-0101 (a first‑in‑class anti‑TLR4 antibody). Novimmune is developing a kappa/lambda body™ bispecific drug platform, including approaches to selectively inhibit CD47 on cancer cells. The company plans to develop and commercialize NI-0501 with its own resources while pursuing partnerships to exploit larger market opportunities for other programs. Novimmune recently strengthened its financial position by closing a CHF 60 million Series B financing. The company is based in Geneva and states an intention to bring medicines to market for orphan disease indications. NovImmune focuses on discovering and developing therapeutic monoclonal antibodies (mAbs) for inflammatory diseases and immune-related disorders. The company has generated seven proprietary mAbs and maintains a pipeline balanced between preclinical and clinical compounds. Three compounds are currently in clinical development, with the most advanced in Phase II. NovImmune has developed a proprietary bispecific antibody generation platform named kappa-lambdabodies™. Management intends to use recent financing to generate proof-of-concept data for at least two compounds, expand the number of partnerships, and complete validation of the kappa-lambdabodies™ platform. The company is headquartered in Geneva, Switzerland.